Thank you for following along with us on our journey to advance antibody science and innovation to improve the lives of patients. On this milestone of reaching 100,000 followers, we want to thank you for following us and encourage you to subscribe to our newsletter: http://gmab.ly/t8Lt50SCGNV.
Om os
We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer
- Websted
-
http://www.genmab.com
Eksternt link til Genmab
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 1.001 – 5.000 medarbejdere
- Hovedkvarter
- Copenhagen V
- Type
- Aktieselskab
Beliggenheder
Medarbejdere hos Genmab
-
Hinrich Göhlmann
Scientific Director specializing in 𝐇𝐢𝐠𝐡-𝐃𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 | Bridging Science, Data, and Technology
-
Amy D.
Director, Digital Products, Experience Management @ Genmab | Digital Transformation | ex-Amex | ex-Regeneron
-
Javier Pintado
Vice President, Global Marketing at Genmab
-
Caroline Eilering
Opdateringer
-
At Genmab, our passion for innovation drives everything we do - from discovering and developing next-gen antibodies to delivering innovative antibody therapeutics to patients. The Annual Genmab Innovation Tournament, now in its 5th year, harnesses our collective creativity to spark new ideas, technologies, and product concepts. This year, we received a record-breaking number of submissions from our colleagues, showcasing how AI and digitalization are transforming our daily work. Congratulations to all the winners and participants! Learn more about our innovative approach: https://bit.ly/3XuqD4t. #AntibodyScience #Innovation
-
Welcome to Genmab’s July Edition of Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines. #culture #news #healthcare
-
At Genmab, we have a “people first” mentality, meaning we foster an extra[not]ordinary™ culture where colleagues truly care about one another. Hear from Alexander Man, Director, Strategy & Corporate Development, as he shares his experience. To #JoinGenmab, visit: https://bit.ly/3LVTzfX. #ExtraNotOrdinary
-
Just In: The European Medicines Agency’s #CHMP has granted a positive opinion recommending approval of our investigational treatment for relapsed/refractory (R/R) follicular lymphoma (FL), developed in partnership with AbbVie Read more: http://gmab.ly/keaE50SrgyB
-
In honor of #CancerImmunotherapyMonth, Genmab recognizes the revolutionary advancements in immunology that are transforming the fight against cancer. Our colleague, Pauline de Goeje, works to design and test new antibody products in the immune-oncology space, with a goal of harnessing the incredible power of our own immune system to target and eliminate tumor cells. Learn more about our unstoppable teams here: http://gmab.ly/F0t150Sqhyo.
-
At Genmab, our extra[not]ordinary™ colleagues are empowered to innovate, build solutions, and execute. Vibeke Leth, Medical Portfolio Operations Manager, shares her perspective on how she emulates these values within her teams. To be part of the extra[not]ordinary™, visit: https://bit.ly/3lTqAPf. #ExtraNotOrdinary #JoinGenmab
-
Genmab is proud to support Out in Science, Technology, Engineering & Mathematics (oSTEM). This Pride Month, oSTEM is awarding scholarships to LGBTQIA+ students pursuing degrees in the sciences at a New Jersey university or college. We’re proud to contribute to this initiative in our local community. To learn more about our Diversity, Equity and Inclusion ambitions, visit: http://gmab.ly/oPv650Sj8lb. #CommunityAtGenmab #PrideMonth
-
In observance of Juneteenth, Genmab is supporting the Stoutsburg Sourland African American Museum. The museum plays a vital role in preserving African American history, educating the public, promoting diversity and inclusion, and fostering a sense of community and cultural pride in New Jersey. We are proud to continue supporting the important work of this museum. To learn more about our DE&I efforts, click here: http://gmab.ly/uFnR50Sk4ta #Juneteenth #CommunityAtGenmab
Tilsvarende sider
Finansiering
Seneste runde
Post IPO-egenkapital134.000.000,00 US$